RxDoctor Payments Data

Carly Fabrizio, DO

Advanced Heart Failure and Transplant Cardiology · Philadelphia, PANPI 1548688948

Payments from drug & device makers

What this record shows

This record is dominated by grants: $22,500 of the $27,731 with a category attached, or 81.1%. Abbott accounts for 92.7% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2020 at $22,551 and has fallen 96.9% since, to $689 in 2025.

$27,731in general payments, 2019–2025

Across 98 payments — averaging $282.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$26K
  • Abiomed$659
  • Impulse Dynamics (USA) Inc.$571
  • AstraZeneca$182
  • E.r. Squibb & Sons, L.L.C.$154
  • Medtronic$140
  • plus $312 from 7 others

What the payments were for

  • Consulting fees$8503%
  • Grants$22,50081%
  • Travel & lodging$1,0954%
  • Food & beverage$3,27512%
  • Education$100%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,731 in reported general payments places this provider in the 75th percentile of 96 advanced heart failure and transplant cardiology providers in Pennsylvania.

See all advanced heart failure and transplant cardiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$75,611
Medicare patients
167
Services billed
467

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis165$4,022,520
EntrestoSacubitril/Valsartan377$371,250
VyndaqelTafamidis Meglumine15$310,115
FarxigaDapagliflozin Propanediol237$183,942
JardianceEmpagliflozin71$71,271
EliquisApixaban40$41,778
Metoprolol Succinate345$3,936
Bumetanide75$2,998
Valsartan64$2,230
Atorvastatin Calcium192$2,078
Hydralazine Hcl81$1,197
Potassium Chloride48$1,166
Spironolactone217$1,140
Carvedilol153$1,117
Torsemide50$1,081

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Vyndaqel, Eliquis$73$4,374,413220 claims
NovartisEntresto$20$371,250377 claims
AstraZenecaFarxiga$182$183,942237 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 96 advanced heart failure and transplant cardiology providers in Pennsylvania.

Other advanced heart failure and transplant cardiology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →